Lifescience Global

JCRUV1N1A18

Image

JCRUV1N1A18

Biological Efficacy of a Dendritic Cell-Based Vaccine in a Patient with Metastatic Colorectal Cancer - Pages 122-128

Mario M. Soldevilla1, Susana Inogés1,2, Ascensión López-Díaz de Cerio1, Fernando Pastor1, Helena Villanueva1 and Maurizio Bendandi1,2

1Lab of Immunotherapy, Oncology Division, Center for Applied Medical Research and 2Immunotherapy Program, Cell Therapy Area, University of Navarra Hospital, Pamplona (Navarra), Spain

DOI: http://dx.doi.org/10.6000/1929-2279.2012.01.01.18

Files

  • Additional Information

    Abstract: Colorectal cancer is a serious health problem affecting de novo more than one million people every year in the developed world. Despite recent advances in the development of novel therapeutic agents, metastatic colorectal cancer remains mostly incurable and its survival rates ominous even when patients respond to the most advanced treatments. Here, we describe a case in which a patient with metastatic colorectal cancer and high risk of relapse remains disease-free while being treated solely with twelve doses of autologous dendritic cells vaccines pulsed with autologous tumor lysate. A sustained, specific immune response elicited by vaccination has also been documented. Prior to receiving this experimental treatment, the patient had undergone both tumor resections and chemotherapy treatments six times, invariably relapsing/progressing within a year from each resection. We believe that the use of autologous vaccines consisting in dendritic cells pulsed with tumor lysate should be further investigate in human clinical trials, particularly in patients with minimal tumor burden and high risk of relapse. We also believe that this type of immunotherapy is more likely to be successful when used as an early rather than merely compassionate treatment option, given the fact that the more toxicity the immune system has received from previous approaches, the less it will be able to respond to tumor vaccination.

    Keywords: Cancer immunotherapy, dendritic cells, metastatic colon cancer, vaccine, tumor lysate, immune response.

    OUR STRENGTHS

    ♦  Worldwide readership
    ♦  High quality content
    ♦  Maximum visibility
    ♦  Efficient publishing
    ♦  Optional Open Access

    Publish your Research

    Survey

    As an author what type of publishing model you prefer?

    780
    Open Access
    493
    Optional Open Access
    338
    Subscription based
    5 Votes left